{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:50:41Z","timestamp":1790884241169,"version":"4.1.0"},"reference-count":246,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-23323186"],"award-info":[{"award-number":["RS-2025-23323186"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Regional Innovation System & Education (RISE) program","award":["2025-RISE-10-002"],"award-info":[{"award-number":["2025-RISE-10-002"]}]},{"DOI":"10.13039\/501100003716","name":"Korea Basic Science Institute","doi-asserted-by":"publisher","award":["RS-2020-NF000330"],"award-info":[{"award-number":["RS-2020-NF000330"]}],"id":[{"id":"10.13039\/501100003716","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Epilepsy affects approximately 50 million people worldwide, with nearly one-third of patients experiencing inadequate seizure control with conventional anti-epileptic drugs. The GABAergic system, responsible for inhibitory neurotransmission in the central nervous system, represents a critical target for seizure management. GABA aminotransferase (GABA-T), the enzyme responsible for GABA catabolism, has emerged as a particularly attractive therapeutic target. Inhibition of GABA-T increases synaptic GABA availability, enhancing inhibitory neurotransmission and raising the seizure threshold. Vigabatrin, an irreversible GABA-T inhibitor, has demonstrated remarkable efficacy in specific epilepsy syndromes, particularly infantile spasms and refractory partial seizures. However, its clinical utility is tempered by the risk of irreversible visual field defects, necessitating careful patient selection and monitoring. This review examines the molecular biology of GABA-T, the mechanisms of action of its inhibitors, clinical applications, safety considerations, and emerging developments in this therapeutic area. We discuss the structure\u2013function relationships of GABA-T, the pharmacology of vigabatrin and experimental inhibitors, clinical efficacy across various epilepsy syndromes, adverse effect profiles, and future directions including novel inhibitors with improved safety profiles. Understanding the role of GABA-T in epilepsy pathophysiology and the therapeutic potential of its inhibitors provides insights into rational drug design and personalized treatment strategies for epilepsy management.<\/jats:p>","DOI":"10.3390\/cimb47121032","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T08:39:18Z","timestamp":1765442358000},"page":"1032","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Molecular Basis of GABA Aminotransferase Inhibition in Epilepsy: Structure, Mechanisms, and Drug Development"],"prefix":"10.3390","volume":"47","author":[{"given":"Muhammad","family":"Yasir","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Kangwon National University School of Medicine, Chuncheon 24341, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0424-1667","authenticated-orcid":false,"given":"Jongseon","family":"Choe","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Kangwon National University School of Medicine, Chuncheon 24341, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0836-6675","authenticated-orcid":false,"given":"Jin-Hee","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Medical Environmental Biology and Tropical Medicine, Kangwon National University School of Medicine, Chuncheon 24341, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1984-3545","authenticated-orcid":false,"given":"Wanjoo","family":"Chun","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Kangwon National University School of Medicine, Chuncheon 24341, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Giourou, E., Stavropoulou-Deli, A., Giannakopoulou, A., Kostopoulos, G.K., and Koutroumanidis, M. (2015). Introduction to epilepsy and related brain disorders. Cyberphysical Systems for Epilepsy and Related Brain Disorders: Multi-Parametric Monitoring and Analysis for Diagnosis and Optimal Disease Management, Springer.","DOI":"10.1007\/978-3-319-20049-1_2"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.15190\/d.2020.7","article-title":"Epileptic seizures","volume":"8","author":"Anwar","year":"2020","journal-title":"Discoveries"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.22270\/jddt.v10i3.4090","article-title":"A review on epilepsy and its management","volume":"10","author":"Potnis","year":"2020","journal-title":"J. Drug Deliv. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Sazgar, M., and Young, M.G. (2019). Seizures and epilepsy. Absolute Epilepsy and EEG Rotation Review: Essentials for Trainees, Springer.","DOI":"10.1007\/978-3-030-03511-2"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.yebeh.2007.12.019","article-title":"The global burden and stigma of epilepsy","volume":"12","author":"Mula","year":"2008","journal-title":"Epilepsy Behav."},{"key":"ref_6","unstructured":"World Health Organization (2022). Improving the Lives of People with Epilepsy: A Technical Brief, World Health Organization."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/epi.14458","article-title":"Epilepsy in Asia: Disease burden, management barriers, and challenges","volume":"60","author":"Trinka","year":"2019","journal-title":"Epilepsia"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Niriayo, Y.L., Gebregziabher, T., Demoz, G.T., Tesfay, N., and Gidey, K. (2024). Drug therapy problems and contributing factors among patients with epilepsy. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0299968"},{"key":"ref_9","first-page":"201","article-title":"Pathophysiology of epilepsy","volume":"100","author":"Engelborghs","year":"2000","journal-title":"Acta Neurol. Belg"},{"key":"ref_10","unstructured":"Cavazos, J.E., and Sanchez, R. (2004). Pathophysiology of seizures and epilepsy. Epilepsy, CRC Press."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s11064-014-1473-1","article-title":"The glutamine\u2013glutamate\/GABA cycle: Function, regional differences in glutamate and GABA production and effects of interference with GABA metabolism","volume":"40","author":"Walls","year":"2015","journal-title":"Neurochem. Res."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Patri, M. (2019). Synaptic transmission and amino acid neurotransmitters. Neurochemical Basis of Brain Function and Dysfunction, IntechOpen.","DOI":"10.5772\/intechopen.82121"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1177\/1535370221989263","article-title":"Influence of glutamate and GABA transport on brain excitatory\/inhibitory balance","volume":"246","author":"Sears","year":"2021","journal-title":"Exp. Biol. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kaur, S., Singh, S., Arora, A., Ram, P., Kumar, S., Kumar, P., and Abed, S.N. (2020). Pharmacology of GABA and its receptors. Frontiers in Pharmacology of Neurotransmitters, Springer.","DOI":"10.1007\/978-981-15-3556-7_8"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Enna, S.J. (2007). The GABA receptors. The GABA Receptors, Springer.","DOI":"10.1007\/978-1-59745-465-0"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Murala, S., Yelam, A., Ismail, M.M., and Bollu, P.C. (2022). Gaba. Neurochemistry in Clinical Practice, Springer.","DOI":"10.1007\/978-3-031-07897-2_4"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kaba\u0142a, K., and Janicka, M. (2024). Relationship between the GABA pathway and signaling of other regulatory molecules. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms251910749"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Jalil, S.U., Ansari, S.A., and Ansari, M.I. (2025). GABA Genetic Engineering\/Genome Editing Aspects. GABA Signaling System and Abiotic Stress Tolerance in Plants, Springer.","DOI":"10.1007\/978-981-95-0437-4"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.3390\/cimb44040096","article-title":"Therapeutic anti-depressant potential of microbial GABA produced by Lactobacillus rhamnosus strains for GABAergic signaling restoration and inhibition of addiction-induced HPA axis hyperactivity","volume":"44","author":"Tette","year":"2022","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kr\u00e4mer, G., and Wohlrab, G.C. (2015). Vigabatrin. The Treatment of Epilepsy, Wiley.","DOI":"10.1002\/9781118936979.ch52"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2165\/00003495-199141060-00007","article-title":"Vigabatrin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control","volume":"41","author":"Grant","year":"1991","journal-title":"Drugs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s41983-023-00696-6","article-title":"Peripheral visual field defect of vigabatrin in pediatric epilepsy: A review","volume":"59","author":"Pathan","year":"2023","journal-title":"Egypt. J. Neurol. Psychiatry Neurosurg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s12264-008-0109-3","article-title":"The role and the mechanism of \u03b3-aminobutyric acid during central nervous system development","volume":"24","author":"Li","year":"2008","journal-title":"Neurosci. Bull."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1017\/cjn.2015.333","article-title":"The long and winding road to gamma-amino-butyric acid as neurotransmitter","volume":"43","author":"Avoli","year":"2016","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s43141-021-00224-0","article-title":"GABAA receptors: Structure, function, pharmacology, and related disorders","volume":"19","author":"Ghit","year":"2021","journal-title":"J. Genet. Eng. Biotechnol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"R\u00edos, J.-L., Schinella, G.R., and Moragrega, I. (2022). Phenolics as GABAA receptor ligands: An updated review. Molecules, 27.","DOI":"10.3390\/molecules27061770"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"M\u00f6hler, H. (2010). Physiology and pharmacology of the GABA system: Focus on GABA receptors. GABA and Sleep: Molecular, Functional and Clinical Aspects, Springer.","DOI":"10.1007\/978-3-0346-0226-6_1"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3390\/nutraceuticals4020015","article-title":"The effect of oral GABA on the nervous system: Potential for therapeutic intervention","volume":"4","author":"Almutairi","year":"2024","journal-title":"Nutraceuticals"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"108505","DOI":"10.1016\/j.pharmthera.2023.108505","article-title":"GABAergic modulation of sleep-wake states","volume":"249","author":"Oishi","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1212\/WNL.0b013e318247cd03","article-title":"GABAB receptors: Structure, functions, and clinical implications","volume":"78","author":"Benarroch","year":"2012","journal-title":"Neurology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"13664","DOI":"10.1039\/C7CP00582B","article-title":"Binding site opening by loop C shift and chloride ion-pore interaction in the GABA A receptor model","volume":"19","author":"Kraszewski","year":"2017","journal-title":"Phys. Chem. Chem. Phys."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/jnc.15769","article-title":"Fundamental neurochemistry review: GABAA receptor neurotransmission and epilepsy: Principles, disease mechanisms and pharmacotherapy","volume":"165","author":"Bryson","year":"2023","journal-title":"J. Neurochem."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"H\u00fcbner, C.A., and Holthoff, K. (2013). Anion transport and GABA signaling. Front. Cell. Neurosci., 7.","DOI":"10.3389\/fncel.2013.00177"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Sieghart, W. (2007). Subunit composition and structure of GABAA-receptor subtypes. The GABA Receptors, Springer.","DOI":"10.1007\/978-1-59745-465-0_4"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1080\/17460441.2019.1599356","article-title":"GABA (A) receptor-targeted drug development-New perspectives in perioperative anesthesia","volume":"14","author":"Antkowiak","year":"2019","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1054-3589(10)58006-2","article-title":"GABAB receptor coupling to G-proteins and ion channels","volume":"58","author":"Padgett","year":"2010","journal-title":"Adv. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-021-03507-1","article-title":"Structural basis of GABAB receptor\u2013Gi protein coupling","volume":"594","author":"Shen","year":"2021","journal-title":"Nature"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Castelli, M.P., and Gessa, G.L. (2016). Distribution and localization of the GABAB receptor. GABAB Receptor, Springer.","DOI":"10.1007\/978-3-319-46044-4_5"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Evenseth, L.S.M., Gabrielsen, M., and Sylte, I. (2020). The GABAB receptor\u2014Structure, ligand binding and drug development. Molecules, 25.","DOI":"10.3390\/molecules25133093"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41586-020-2469-4","article-title":"Structures of metabotropic GABAB receptor","volume":"584","author":"Robertson","year":"2020","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Kantamneni, S. (2016). Modulation of neurotransmission by the GABAB receptor. GABAB Receptor, Springer.","DOI":"10.1007\/978-3-319-46044-4_7"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1146\/annurev-pharmtox-010919-023755","article-title":"Neurons, receptors, and channels","volume":"60","author":"Brown","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s12272-019-01196-z","article-title":"The regulation of glutamic acid decarboxylases in GABA neurotransmission in the brain","volume":"42","author":"Lee","year":"2019","journal-title":"Arch. Pharmacal Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.brainres.2007.04.008","article-title":"Role of glutamate decarboxylase (GAD) isoform, GAD65, in GABA synthesis and transport into synaptic vesicles\u2014Evidence from GAD65-knockout mice studies","volume":"1154","author":"Wu","year":"2007","journal-title":"Brain Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1381-1177(00)00114-4","article-title":"Enzymatic and structural aspects on glutamate decarboxylase","volume":"10","author":"Ueno","year":"2000","journal-title":"J. Mol. Catal. B Enzym."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.neuint.2009.01.020","article-title":"A novel mechanism for GABA synthesis and packaging into synaptic vesicles","volume":"55","author":"Buddhala","year":"2009","journal-title":"Neurochem. Int."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Bolneo, E., Chau, P.Y.S., Noakes, P.G., and Bellingham, M.C. (2022). Investigating the role of GABA in neural development and disease using mice lacking GAD67 or VGAT genes. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23147965"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Kanaani, J., Cianciaruso, C., Phelps, E.A., Pasquier, M., Brioudes, E., Billestrup, N., and Baekkeskov, S. (2015). Compartmentalization of GABA synthesis by GAD67 differs between pancreatic beta cells and neurons. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0117130"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/jnr.20171","article-title":"Changes in GABA transporters in the rat hippocampus after kainate-induced neuronal injury: Decrease in GAT-1 and GAT-3 but upregulation of betaine\/GABA transporter BGT-1","volume":"77","author":"Zhu","year":"2004","journal-title":"J. Neurosci. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1134\/S0022093023030055","article-title":"Anticonvulsant Efficacy of Inhibition of Synaptic and Extrasynaptic GABA-Transporters in the Prevention of Hyperbaric Oxygen Seizures","volume":"59","author":"Alekseeva","year":"2023","journal-title":"J. Evol. Biochem. Physiol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"\u0141\u0105tka, K., and Bajda, M. (2022). Analysis of different binding modes for tiagabine within the GAT-1 transporter. Biomolecules, 12.","DOI":"10.3390\/biom12111663"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e18712","DOI":"10.7717\/peerj.18712","article-title":"Insights and progress on the biosynthesis, metabolism, and physiological functions of gamma-aminobutyric acid (GABA): A review","volume":"12","author":"Zhang","year":"2024","journal-title":"PeerJ"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Jalil, S.U., Ansari, S.A., and Ansari, M.I. (2025). GABA Transporters and Their Function in Stress Tolerance. GABA Signaling System and Abiotic Stress Tolerance in Plants, Springer.","DOI":"10.1007\/978-981-95-0437-4"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"106935","DOI":"10.1016\/j.yebeh.2020.106935","article-title":"GABAergic interneurons in epilepsy: More than a simple change in inhibition","volume":"121","author":"Marafiga","year":"2021","journal-title":"Epilepsy Behav."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41582-022-00651-8","article-title":"The metabolic basis of epilepsy","volume":"18","author":"Rho","year":"2022","journal-title":"Nat. Rev. Neurol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/978-1-4757-6376-8_7","article-title":"GABA and its receptors in epilepsy","volume":"548","author":"Sperk","year":"2004","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1046\/j.1528-1157.2001.042suppl.3008.x","article-title":"GABAergic mechanisms in epilepsy","volume":"42","author":"Treiman","year":"2001","journal-title":"Epilepsia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.seizure.2021.06.028","article-title":"Brain concentrations of glutamate and GABA in human epilepsy: A review","volume":"91","author":"Sarlo","year":"2021","journal-title":"Seizure"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1007\/s00259-024-07054-5","article-title":"Transcriptionally downregulated GABAergic genes associated with synaptic density network dysfunction in temporal lobe epilepsy","volume":"52","author":"Li","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.seizure.2022.07.007","article-title":"Genetic variations in GABA metabolism and epilepsy","volume":"101","author":"Feng","year":"2022","journal-title":"Seizure"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00401-024-02737-7","article-title":"Impaired GABAergic regulation and developmental immaturity in interneurons derived from the medial ganglionic eminence in the tuberous sclerosis complex","volume":"147","author":"Scheper","year":"2024","journal-title":"Acta Neuropathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/gbb.12321","article-title":"GABAA receptor subtype involvement in addictive behaviour","volume":"16","author":"Stephens","year":"2017","journal-title":"Genes Brain Behav."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.pharmthera.2012.08.006","article-title":"\u03b12-containing GABAA receptors: A target for the development of novel treatment strategies for CNS disorders","volume":"136","author":"Engin","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1177\/08830738241273437","article-title":"GABA (A) Receptor Subunit (\u03b32, \u03b4, \u03b21-3) Variants in Genetic Epilepsy: A Comprehensive Summary of 206 Clinical Cases","volume":"39","author":"Zhu","year":"2024","journal-title":"J. Child Neurol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1111\/jnc.15932","article-title":"GABAA receptors in epilepsy: Elucidating phenotypic divergence through functional analysis of genetic variants","volume":"168","author":"Absalom","year":"2024","journal-title":"J. Neurochem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/s13287-024-04018-2","article-title":"In vitro electrophysiological drug testing on neuronal networks derived from human induced pluripotent stem cells","volume":"15","author":"Parodi","year":"2024","journal-title":"Stem Cell Res. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1007\/s10565-023-09803-y","article-title":"GABAA receptor-mediated seizure liabilities: A mixed-methods screening approach","volume":"39","author":"Bampali","year":"2023","journal-title":"Cell Biol. Toxicol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40263-023-01027-2","article-title":"New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: I. Role of GABA as a Modulator of Seizure Activity and Recently Approved Medications Acting on the GABA System","volume":"37","author":"Perucca","year":"2023","journal-title":"CNS Drugs"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/s41467-021-21477-w","article-title":"Dysregulation of REV-ERB\u03b1 impairs GABAergic function and promotes epileptic seizures in preclinical models","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41420-025-02759-4","article-title":"A knock-in mouse model for GABRG2-related epileptic encephalopathy displays spontaneous generalized seizures and cognitive impairment","volume":"11","author":"Shen","year":"2025","journal-title":"Cell Death Discov."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Han, H.A., Cortez, M.A., and Snead, O.C. (2012). GABAB receptor and absence epilepsy. Jasper\u2019s Basic Mechanisms of the Epilepsies, National Center for Biotechnology Information. [4th ed.].","DOI":"10.1093\/med\/9780199746545.003.0019"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.neubiorev.2010.10.002","article-title":"Evidence for GABAergic inhibitory deficits in major depressive disorder","volume":"35","author":"Croarkin","year":"2011","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1152\/physrev.00007.2017","article-title":"Hippocampal GABAergic inhibitory interneurons","volume":"97","author":"Pelkey","year":"2017","journal-title":"Physiol. Rev."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.3390\/ph3113461","article-title":"Allosteric modulation of \u03b1\u03b2\u03b4 GABAA receptors","volume":"3","author":"Feng","year":"2010","journal-title":"Pharmaceuticals"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/7854_2021_232","article-title":"GABAB receptor chemistry and pharmacology: Agonists, antagonists, and allosteric modulators","volume":"52","author":"Nieto","year":"2021","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2147\/JEP.S242964","article-title":"Experimental GABA A receptor agonists and allosteric modulators for the treatment of focal epilepsy","volume":"13","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41583-023-00724-7","article-title":"GABA tone regulation and its cognitive functions in the brain","volume":"24","author":"Koh","year":"2023","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"109149","DOI":"10.1016\/j.ymgme.2025.109149","article-title":"Biochemical investigation of pathogenic missense mutations of human 4-amino butyrate aminotransferase towards the understanding of the molecular pathogenesis of GABA transaminase deficiency","volume":"145","author":"Ambrosini","year":"2025","journal-title":"Mol. Genet. Metab."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/mmi.12861","article-title":"Role of the aminotransferase domain in B acillus subtilis GabR, a pyridoxal 5\u2032-phosphate-dependent transcriptional regulator","volume":"95","author":"Okuda","year":"2015","journal-title":"Mol. Microbiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1021\/acs.chemrev.8b00009","article-title":"Design and mechanism of GABA aminotransferase inactivators. Treatments for epilepsies and addictions","volume":"118","author":"Silverman","year":"2018","journal-title":"Chem. Rev."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1080\/14756366.2021.1975697","article-title":"High-yield synthesis and purification of recombinant human GABA transaminase for high-throughput screening assays","volume":"36","author":"Park","year":"2021","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e4471","DOI":"10.1002\/pro.4471","article-title":"Characterization of the Escherichia coli pyridoxal 5\u2032-phosphate homeostasis protein (YggS): Role of lysine residues in PLP binding and protein stability","volume":"31","author":"Tramonti","year":"2022","journal-title":"Protein Sci."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Tran, J.U., and Brown, B.L. (2022). Structural basis for allostery in PLP-dependent enzymes. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.884281"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Roura Padrosa, D., Alaux, R., Smith, P., Dreveny, I., L\u00f3pez-Gallego, F., and Paradisi, F. (2019). Enhancing PLP-binding capacity of class-III \u03c9-transaminase by single residue substitution. Front. Bioeng. Biotechnol., 7.","DOI":"10.3389\/fbioe.2019.00282"},{"key":"ref_85","unstructured":"Giraudo, A. (2018). Development of Innovative GABAa Receptor Ligands Using a Bioisosteric Approach. [Ph.D. Thesis, University of Turin]."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e70029","DOI":"10.1111\/jnc.70029","article-title":"The Glutamate\/GABA-Glutamine Cycle: Insights, Updates, and Advances","volume":"169","author":"Andersen","year":"2025","journal-title":"J. Neurochem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neuint.2017.03.008","article-title":"Catabolism of GABA, succinic semialdehyde or gamma-hydroxybutyrate through the GABA shunt impair mitochondrial substrate-level phosphorylation","volume":"109","author":"Ravasz","year":"2017","journal-title":"Neurochem. Int."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Hertz, L., and Rothman, D.L. (2016). Glucose, lactate, \u03b2-hydroxybutyrate, acetate, GABA, and succinate as substrates for synthesis of glutamate and GABA in the glutamine\u2013glutamate\/GABA cycle. The Glutamate\/GABA-Glutamine Cycle: Amino Acid Neurotransmitter Homeostasis, Springer.","DOI":"10.1007\/978-3-319-45096-4_2"},{"key":"ref_89","unstructured":"Brikis, C. (2015). Characterization of Glyoxylate\/Succinic Semialdehyde Reductases in Plants and Impact of Elevated CO2 on \u03b3-Aminobutyrate Metabolism in \u2018Empire\u2019 Apple Fruit Stored Under Controlled Atmosphere Conditions, University of Guelph."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cbi.2018.06.004","article-title":"NMDA and GABA receptor presence in rat heart mitochondria","volume":"291","author":"Nesterov","year":"2018","journal-title":"Chem.-Biol. Interact."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s11064-021-03463-2","article-title":"Coupling of GABA metabolism to mitochondrial glucose phosphorylation","volume":"47","author":"Galina","year":"2022","journal-title":"Neurochem. Res."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Scimemi, A. (2014). Structure, function, and plasticity of GABA transporters. Front. Cell. Neurosci., 8.","DOI":"10.3389\/fncel.2014.00161"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/jnc.15811","article-title":"Milestone Review: Metabolic dynamics of glutamate and GABA mediated neurotransmission\u2014The essential roles of astrocytes","volume":"166","author":"Andersen","year":"2023","journal-title":"J. Neurochem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1042\/EBC20220208","article-title":"Astrocytes regulate inhibitory neurotransmission through GABA uptake, metabolism, and recycling","volume":"67","author":"Andersen","year":"2023","journal-title":"Essays Biochem."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Si, W., Li, H., Kang, T., Ye, J., Yao, Z., Liu, Y., Yu, T., Zhang, Y., Ling, Y., and Cao, H. (2020). Effect of gaba-t on reproductive function in female rats. Animals, 10.","DOI":"10.3390\/ani10040567"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Eprintsev, A.T., Anokhina, G.B., Shakhov, Z.N., Moskvina, P.P., and Igamberdiev, A.U. (2024). The Role of Glutamate Metabolism and the GABA Shunt in Bypassing the Tricarboxylic Acid Cycle in the Light. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252312711"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10725-021-00710-y","article-title":"GABA shunt: A key-player in mitigation of ROS during stress","volume":"94","author":"Ansari","year":"2021","journal-title":"Plant Growth Regul."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Jalil, S.U., Ansari, S.A., and Ansari, M.I. (2025). GABA and Physiological Response Against Hypoxia Stress. GABA Signaling System and Abiotic Stress Tolerance in Plants, Springer.","DOI":"10.1007\/978-981-95-0437-4"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Schousboe, A., Bak, L.K., and Waagepetersen, H.S. (2013). Astrocytic control of biosynthesis and turnover of the neurotransmitters glutamate and GABA. Front. Endocrinol., 4.","DOI":"10.3389\/fendo.2013.00102"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"36009","DOI":"10.1038\/srep36009","article-title":"Transcriptome analysis uncovers key regulatory and metabolic aspects of soybean embryonic axes during germination","volume":"6","author":"Ribeiro","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11655-019-2944-7","article-title":"Pinellia total alkaloids modulate the GABAergic system in hippocampal formation on pilocarpine-induced epileptic rats","volume":"26","author":"Deng","year":"2020","journal-title":"Chin. J. Integr. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/1073858411422114","article-title":"Development of the GABAergic system from birth to adolescence","volume":"18","author":"Kilb","year":"2012","journal-title":"Neuroscientist"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Kilb, W., Kirischuk, S., and Luhmann, H.J. (2013). Role of tonic GABAergic currents during pre-and early postnatal rodent development. Front. Neural Circuits, 7.","DOI":"10.3389\/fncir.2013.00139"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Deidda, G., Bozarth, I.F., and Cancedda, L. (2014). Modulation of GABAergic transmission in development and neurodevelopmental disorders: Investigating physiology and pathology to gain therapeutic perspectives. Front. Cell. Neurosci., 8.","DOI":"10.3389\/fncel.2014.00119"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1023\/A:1022580506443","article-title":"Neuroactive amino acids in focally epileptic human brain: A review","volume":"24","author":"Sherwin","year":"1999","journal-title":"Neurochem. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.neuron.2015.03.042","article-title":"The GABAA receptor as a therapeutic target for neurodevelopmental disorders","volume":"86","author":"Braat","year":"2015","journal-title":"Neuron"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Cazorla, \u00c1., Artuch, R., and Pearl, P.L. (2022). Disorders of neurotransmission. Inborn Metabolic Diseases: Diagnosis and Treatment, Springer.","DOI":"10.1007\/978-3-662-63123-2_30"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3233\/PEP-14097","article-title":"Disorders of GABA metabolism: SSADH and GABA-transaminase deficiencies","volume":"3","author":"Parviz","year":"2014","journal-title":"J. Pediatr. Epilepsy"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.pnpbp.2010.06.013","article-title":"The role of glutamate on the action of antidepressants","volume":"35","author":"Hashimoto","year":"2011","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3174\/ajnr.A2902","article-title":"GABA-based evaluation of neurologic conditions: MR spectroscopy","volume":"34","author":"Levy","year":"2013","journal-title":"Am. J. Neuroradiol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/jmri.24611","article-title":"Investigation of glutamine and GABA levels in patients with idiopathic generalized epilepsy using MEGAPRESS","volume":"41","author":"Chowdhury","year":"2015","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s12276-025-01398-0","article-title":"Suppressing astrocytic GABA transaminase enhances tonic inhibition and weakens hippocampal spatial memory","volume":"57","author":"Park","year":"2025","journal-title":"Exp. Mol. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1042\/BCJ20170814","article-title":"Propionate enters GABAergic neurons, inhibits GABA transaminase, causes GABA accumulation and lethargy in a model of propionic acidemia","volume":"475","author":"Morland","year":"2018","journal-title":"Biochem. J."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1528-1157.2001.077889.x","article-title":"Effects of vigabatrin on brain GABA+\/CR signals in patients with epilepsy monitored by 1H-NMR-spectroscopy: Responder characteristics","volume":"42","author":"Mueller","year":"2001","journal-title":"Epilepsia"},{"key":"ref_115","first-page":"139","article-title":"Pharmacological profile of the GABA-transaminase inhibitor vigabatrin","volume":"4","author":"Sherif","year":"2015","journal-title":"World J. Pharm. Pharm. Sci."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s12264-023-01138-2","article-title":"Development of SV2A ligands for epilepsy treatment: A review of levetiracetam, brivaracetam, and padsevonil","volume":"40","author":"Wu","year":"2024","journal-title":"Neurosci. Bull."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.2174\/092986710791698549","article-title":"A role of GABA analogues in the treatment of neurological diseases","volume":"17","author":"Gajcy","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Kamieniak, M., Ko\u015bmider, K., Miziak, B., and Czuczwar, S.J. (2024). The Oxidative Stress in Epilepsy\u2014Focus on Melatonin. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252312943"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1111\/epi.14557","article-title":"Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). I. Drugs in preclinical and early clinical development","volume":"59","author":"Bialer","year":"2018","journal-title":"Epilepsia"},{"key":"ref_120","unstructured":"Maragakis, N.J. (2012). The challenges of translational medicine. Translational Neuroscience: Applications in Psychiatry, Neurology, and Neurodevelopmental Disorders, Cambridge University Press."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"114537","DOI":"10.1016\/j.expneurol.2023.114537","article-title":"Epilepsy plus blindness in microdeletion of GABRA1 and GABRG2 in mouse and human","volume":"369","author":"Zhang","year":"2023","journal-title":"Exp. Neurol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/14728222.2022.2039120","article-title":"Emerging therapeutic targets for epilepsy: Preclinical insights","volume":"26","author":"Czuczwar","year":"2022","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Maheshwari, A., Nahm, W.K., and Noebels, J.L. (2013). Paradoxical proepileptic response to NMDA receptor blockade linked to cortical interneuron defect in stargazer mice. Front. Cell. Neurosci., 7.","DOI":"10.3389\/fncel.2013.00156"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s13577-024-01126-2","article-title":"GABAA receptor modulation by the endocannabinoid system: Insights into the regulatory mechanisms involving glutamine synthetase and MAPK mediators","volume":"37","author":"Pakkhesal","year":"2024","journal-title":"Hum. Cell"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"180165","DOI":"10.1098\/rsob.180165","article-title":"Insights into GABAAergic system alteration in Huntington\u2019s disease","volume":"8","author":"Hsu","year":"2018","journal-title":"R. Soc. Open Biol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"21753","DOI":"10.1038\/srep21753","article-title":"Depolarizing GABA\/glycine synaptic events switch from excitation to inhibition during frequency increases","volume":"6","author":"Branchereau","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1152\/physrev.00043.2010","article-title":"Fast synaptic inhibition in spinal sensory processing and pain control","volume":"92","author":"Zeilhofer","year":"2012","journal-title":"Physiol. Rev."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.pharmthera.2009.11.007","article-title":"Neuronal and non-neuronal GABA transporters as targets for antiepileptic drugs","volume":"125","author":"Madsen","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00702-009-0186-0","article-title":"Elevated endogenous GABA concentration attenuates glutamate-glutamine cycling between neurons and astroglia","volume":"116","author":"Yang","year":"2009","journal-title":"J. Neural Transm."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Wang, P., Eshaq, R.S., Meshul, C.K., Moore, C., Hood, R.L., and Leidenheimer, N.J. (2015). Neuronal gamma-aminobutyric acid (GABA) type A receptors undergo cognate ligand chaperoning in the endoplasmic reticulum by endogenous GABA. Front. Cell. Neurosci., 9.","DOI":"10.3389\/fncel.2015.00188"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41592-019-0471-2","article-title":"A genetically encoded fluorescent sensor for in vivo imaging of GABA","volume":"16","author":"Marvin","year":"2019","journal-title":"Nat. Methods"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S1474-4422(20)30035-1","article-title":"30 years of second-generation antiseizure medications: Impact and future perspectives","volume":"19","author":"Perucca","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Koshal, P., Jamwal, S., Akula, K.K., and Bansal, P.K. (2018). Animal Models of Epilepsy. Animal Models of Neurological Disorders: Principle and Working Procedure for Animal Models of Neurological Disorders, Springer.","DOI":"10.1007\/978-981-10-5981-0_5"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Rissardo, J.P., and Fornari Caprara, A.L. (2023). Cenobamate (YKP3089) and drug-resistant epilepsy: A review of the literature. Medicina, 59.","DOI":"10.3390\/medicina59081389"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/1073858417701382","article-title":"GABAergic transmission during brain development: Multiple effects at multiple stages","volume":"24","author":"Kirmse","year":"2018","journal-title":"Neuroscientist"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11011-014-9560-1","article-title":"GABA receptors in brain development, function, and injury","volume":"30","author":"Wu","year":"2015","journal-title":"Metab. Brain Dis."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s40263-016-0384-x","article-title":"Synaptic vesicle glycoprotein 2A ligands in the treatment of epilepsy and beyond","volume":"30","author":"Gillard","year":"2016","journal-title":"CNS Drugs"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Xu, Z., Liu, Y., Wei, P., Feng, K., Niu, J., Shen, G., Lu, W., Xiao, W., Wang, J., and Smagghe, G.J. (2017). High gama-aminobutyric acid contents involved in abamectin resistance and predation, an interesting phenomenon in spider mites. Front. Physiol., 8.","DOI":"10.3389\/fphys.2017.00216"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"109301","DOI":"10.1016\/j.celrep.2021.109301","article-title":"A critical role of hepatic GABA in the metabolic dysfunction and hyperphagia of obesity","volume":"35","author":"Geisler","year":"2021","journal-title":"Cell Rep."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cmet.2015.02.008","article-title":"The GABA transaminase, ABAT, is essential for mitochondrial nucleoside metabolism","volume":"21","author":"Besse","year":"2015","journal-title":"Cell Metab."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s10545-016-9951-z","article-title":"Phenotyping GABA transaminase deficiency: A case description and literature review","volume":"39","author":"Louro","year":"2016","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.braindev.2016.08.005","article-title":"Hypersomnolence-hyperkinetic movement disorder in a child with compound heterozygous mutation in 4-aminobutyrate aminotransferase (ABAT) gene","volume":"39","author":"Nagappa","year":"2017","journal-title":"Brain Dev."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s11515-013-1270-2","article-title":"Novel functions of GABA signaling in adult neurogenesis","volume":"8","author":"Pontes","year":"2013","journal-title":"Front. Biol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/epi.13785","article-title":"Neuroinflammation in epileptogenesis: Insights and translational perspectives from new models of epilepsy","volume":"58","author":"White","year":"2017","journal-title":"Epilepsia"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"fcae110","DOI":"10.1093\/braincomms\/fcae110","article-title":"\u03b3-Aminobutyric acid transporter and GABA(A) receptor mechanisms in Slc6a1(+\/A288V) and Slc6a1(+\/S295L) mice associated with developmental and epileptic encephalopathies","volume":"6","author":"Shen","year":"2024","journal-title":"Brain Commun."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Randhave, K., Zavalin, K., and Kang, J.-Q. (2025). 4-Phenylbutyrate Rescues Neurobehavioral Phenotypes in SLC6A1-Related Encephalopathy. Epilepsy Res., 107708.","DOI":"10.1016\/j.eplepsyres.2025.107708"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3349\/ymj.2024.0325","article-title":"Therapeutic approach to epilepsy in patients with mitochondrial diseases","volume":"66","author":"Na","year":"2025","journal-title":"Yonsei Med. J."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Conte, E., Boccanegra, B., Dinoi, G., Pusch, M., De Luca, A., Liantonio, A., and Imbrici, P. (2024). Therapeutic approaches to tuberous sclerosis complex: From available therapies to promising drug targets. Biomolecules, 14.","DOI":"10.3390\/biom14091190"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Wang, J., Zhang, G., Huang, S., Wei, M., Wu, Y., and Xie, Z. (2025). Dravet syndrome: Novel insights into SCN1A-mediated epileptic neurodevelopmental disorders within the molecular diagnostic-therapeutic framework. Front. Neurosci., 19.","DOI":"10.3389\/fnins.2025.1634718"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1080\/10739149.2013.876545","article-title":"Critical review on the analytical methods for the determination of zwitterionic antiepileptic drugs\u2014Vigabatrin, pregabalin, and gabapentin\u2014In bulk and formulations","volume":"42","author":"Dotsikas","year":"2014","journal-title":"Instrum. Sci. Technol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2174\/1389200218666170406115350","article-title":"Metabolism of drugs used in the therapy of seizures: An analytical point of view. Part 1","volume":"18","author":"Mandrioli","year":"2017","journal-title":"Curr. Drug Metab."},{"key":"ref_152","first-page":"S95","article-title":"Vigabatrin","volume":"36","year":"1995","journal-title":"Epilepsia"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/106002809302700215","article-title":"Vigabatrin","volume":"27","author":"Connelly","year":"1993","journal-title":"Ann. Pharmacother."},{"key":"ref_154","first-page":"114","article-title":"Enzymes as targets of Drug Action: An Overview","volume":"3","author":"Seetharaman","year":"2020","journal-title":"Int. J."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"10711","DOI":"10.1021\/jacs.9b03254","article-title":"Mechanism of Inactivation of Ornithine Aminotransferase by (1 S, 3 S)-3-Amino-4-(hexafluoropropan-2-ylidenyl) cyclopentane-1-carboxylic Acid","volume":"141","author":"Moschitto","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ddr.430210302","article-title":"GABA receptors and GABAergic synapses as targets for drug development","volume":"21","author":"Taylor","year":"1990","journal-title":"Drug Dev. Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1038\/npp.2014.79","article-title":"Neuropharmacological and neurobiological relevance of in vivo 1H-MRS of GABA and glutamate for preclinical drug discovery in mental disorders","volume":"39","author":"Waschkies","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.2174\/0929867328666210910124727","article-title":"Drug treatment of epilepsy: From serendipitous discovery to evolutionary mechanisms","volume":"29","author":"Lou","year":"2022","journal-title":"Curr. Med. Chem."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(89)90389-0","article-title":"Anticonvulsant and proconvulsant effects of inhibitors of GABA degradation in the amygdala-kindling model","volume":"163","year":"1989","journal-title":"Eur. J. Pharmacol."},{"key":"ref_160","unstructured":"Shorvon, S. (2009). History of the Drug Treatment of Epilepsy Between 1955 and 1989 with Special Reference to the Role of the International League Against Epilepsy (ILAE). Treat. Epilepsy."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/WNO.0000000000000609","article-title":"Vigabatrin: Lessons learned from the United States experience","volume":"38","author":"Foroozan","year":"2018","journal-title":"J. Neuro-Ophthalmol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1600-0404.2011.01598.x","article-title":"Vigabatrin therapy for refractory complex partial seizures: Review of clinical trial experience in the United States","volume":"124","author":"Faught","year":"2011","journal-title":"Acta Neurol. Scand."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1517\/14656566.2016.1161026","article-title":"Stiripentol and vigabatrin current roles in the treatment of epilepsy","volume":"17","author":"Chiron","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1592\/phco.31.3.298","article-title":"Vigabatrin for infantile spasms","volume":"31","author":"Pesaturo","year":"2011","journal-title":"Pharmacotherapy"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/j.1528-1157.1999.tb00802.x","article-title":"Treatment of infantile spasms: Results of a population-based study with vigabatrin as the first drug for spasms","volume":"40","author":"Gaily","year":"1999","journal-title":"Epilepsia"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1021\/acs.biochem.8b00315","article-title":"The taxonomy of covalent inhibitors","volume":"57","author":"Tuley","year":"2018","journal-title":"Biochemistry"},{"key":"ref_167","first-page":"273","article-title":"7.10-pyridoxal 5\u2032-phosphate-dependent enzymes: Catalysis, conformation, and genomics","volume":"7","author":"Raboni","year":"2010","journal-title":"Compr. Nat. Prod. II"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-0404.2011.01596.x","article-title":"Mechanism of action of vigabatrin: Correcting misperceptions","volume":"124","year":"2011","journal-title":"Acta Neurol. Scand."},{"key":"ref_169","first-page":"295","article-title":"Mechanisms of action of antiepileptic drugs","volume":"25","author":"Sills","year":"2011","journal-title":"Epilepsy"},{"key":"ref_170","first-page":"19","article-title":"A review on antiepileptic drug and their uses, mechanism of actions, adverse effects and drug interaction","volume":"2","author":"Asif","year":"2016","journal-title":"Curr. Sci. Perspect."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"101934","DOI":"10.1016\/j.jsps.2023.101934","article-title":"Pharmacokinetics and tissue distribution of vigabatrin enantiomers in rats","volume":"32","author":"Zheng","year":"2024","journal-title":"Saudi Pharm. J."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jchromb.2017.10.037","article-title":"Determination of the R (\u2212) and S (+)-enantiomers of vigabatrin in human plasma by ultra-high-performance liquid chromatography and tandem mass-spectrometry","volume":"1070","author":"Duhamel","year":"2017","journal-title":"J. Chromatogr. B"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/01926233231179147","article-title":"Retinal and systemic toxicity of vigabatrin is driven by the S-enantiomer in the long Evans rat","volume":"51","author":"Rasmussen","year":"2023","journal-title":"Toxicol. Pathol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"927","DOI":"10.4155\/tde.14.55","article-title":"Pharmacokinetic aspects of the anti-epileptic drug substance vigabatrin: Focus on transporter interactions","volume":"5","author":"Holm","year":"2014","journal-title":"Ther. Deliv."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"e00036","DOI":"10.1002\/prp2.36","article-title":"Intestinal absorption of the antiepileptic drug substance vigabatrin is altered by infant formula in vitro and in vivo","volume":"2","author":"Thale","year":"2014","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_176","unstructured":"Kalasapur, A.S. (2018). A Comparative Study of the Efficacy and Safety of Sodium Valproate V\/S Magnesium Valproate in Generalized Tonic Clonic Seizures in Neurology OPD, Rajiv Gandhi University of Health Sciences."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40262-013-0107-0","article-title":"Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment","volume":"53","author":"Anderson","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Patsalos, P.N. (2016). Vigabatrin. Antiepileptic Drug Interactions: A Clinical Guide, Springer International Publishing.","DOI":"10.1007\/978-3-319-32909-3"},{"key":"ref_179","first-page":"731","article-title":"Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms","volume":"6","author":"Lerner","year":"2010","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s11030-020-10068-4","article-title":"Rational approaches for the design of various GABA modulators and their clinical progression","volume":"25","author":"Bhagat","year":"2021","journal-title":"Mol. Divers."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Lozada, J., Tovar-Gudi\u00f1o, E., Guevara-Salazar, J.A., Razo-Hern\u00e1ndez, R.S., Santiago, \u00c1., Pastor, N., and Fern\u00e1ndez-Zertuche, M. (2018). QSAR and molecular docking studies of the inhibitory activity of novel heterocyclic GABA analogues over GABA-AT. Molecules, 23.","DOI":"10.3390\/molecules23112984"},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Tovar-Gudi\u00f1o, E., Guevara-Salazar, J.A., Bahena-Herrera, J.R., Trujillo-Ferrara, J.G., Mart\u00ednez-Campos, Z., Razo-Hern\u00e1ndez, R.S., Santiago, \u00c1., Pastor, N., and Fern\u00e1ndez-Zertuche, M. (2018). Novel-substituted heterocyclic GABA analogues. Enzymatic activity against the GABA-AT enzyme from Pseudomonas fluorescens and in silico molecular modeling. Molecules, 23.","DOI":"10.3390\/molecules23051128"},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Puranik, N., and Song, M. (2025). Therapeutic role of heterocyclic compounds in neurodegenerative diseases: Insights from Alzheimer\u2019s and Parkinson\u2019s diseases. Neurol. Int., 17.","DOI":"10.3390\/neurolint17020026"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.2174\/1381612823666170809100524","article-title":"Antiepileptic drugs in clinical development: Differentiate or die?","volume":"23","author":"Zaccara","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1021\/jm201650r","article-title":"The 2011 EB Hershberg Award for important discoveries in medicinally active substances:(1 S, 3 S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile spasms","volume":"55","author":"Silverman","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1080\/14737175.2021.1992275","article-title":"Novel and emerging therapeutics for genetic epilepsies","volume":"21","author":"Gojak","year":"2021","journal-title":"Expert Rev. Neurother."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Khorkova, O., Hsiao, J., and Wahlestedt, C. (2021). Nucleic acid\u2013based therapeutics in orphan neurological disorders: Recent developments. Front. Mol. Biosci., 8.","DOI":"10.3389\/fmolb.2021.643681"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1111\/febs.15258","article-title":"Angelman syndrome: A journey through the brain","volume":"287","author":"Maranga","year":"2020","journal-title":"FEBS J."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.1016\/j.bmc.2015.06.038","article-title":"Synthesis of new fluorinated analogs of GABA, Pregabalin bioisosteres, and their effects on [3H] GABA uptake by rat brain nerve terminals","volume":"23","author":"Borisova","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1021\/ja512299n","article-title":"Mechanism of Inactivation of \u03b3-Aminobutyric Acid Aminotransferase by (1S,3S)-3-Amino-4-difluoromethylene-1-cyclopentanoic Acid (CPP-115)","volume":"137","author":"Lee","year":"2015","journal-title":"J. Am. Chem. Soc."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1167\/iovs.61.2.17","article-title":"Vigabatrin-Induced Retinal Functional Alterations and Second-Order Neuron Plasticity in C57BL\/6J Mice","volume":"61","author":"Chan","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1021\/ml1001344","article-title":"Novel Cyclic Phosphinic Acids as GABAC \u03c1 Receptor Antagonists: Design, Synthesis, and Pharmacology","volume":"2","author":"Gavande","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1016\/j.bmcl.2018.08.031","article-title":"Design and synthesis of cyclopropane-based conformationally restricted GABA analogues as selective inhibitors for betaine\/GABA transporter 1","volume":"28","author":"Suemasa","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neuron.2011.12.012","article-title":"Extrasynaptic GABA(A) receptors: Their function in the CNS and implications for disease","volume":"73","author":"Brickley","year":"2012","journal-title":"Neuron"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"e1024","DOI":"10.1212\/WNL.0000000000011409","article-title":"The STARS phase 2 study: A randomized controlled trial of gaboxadol in Angelman syndrome","volume":"96","author":"Bird","year":"2021","journal-title":"Neurology"},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Richardson, B.D., Ling, L.L., Uteshev, V.V., and Caspary, D.M. (2011). Extrasynaptic GABAA Receptors and Tonic Inhibition in Rat Auditory Thalamus. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0016508"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/epi.12424","article-title":"CPP-115, a vigabatrin analogue, decreases spasms in the multiple-hit rat model of infantile spasms","volume":"55","author":"Briggs","year":"2014","journal-title":"Epilepsia"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1021\/jm201231w","article-title":"(1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a potent \u03b3-aminobutyric acid aminotransferase inactivator for the treatment of cocaine addiction","volume":"55","author":"Pan","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ebcr.2016.08.002","article-title":"A case report on the efficacy of vigabatrin analogue (1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115) in a patient with infantile spasms","volume":"6","author":"Doumlele","year":"2016","journal-title":"Epilepsy Behav. Case Rep."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/sj.bjp.0701383","article-title":"Effect of chronic treatment with the GABA transaminase inhibitors \u03b3-vinyl GABA and ethanolamine O-sulphate on the in vitro GABA release from rat hippocampus","volume":"122","author":"Qume","year":"1997","journal-title":"Br. J. Pharmacol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/0006-2952(87)90112-2","article-title":"Micro-vacuolation in rat brains after long term administration of GABA-transaminase inhibitors: Comparison of effects of ethanolamine-O-sulphate and vigabatrin","volume":"36","author":"John","year":"1987","journal-title":"Biochem. Pharmacol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/sj.bjp.0706557","article-title":"Vigabatrin transport across the human intestinal epithelial (Caco-2) brush-border membrane is via the H+ -coupled amino-acid transporter hPAT1","volume":"147","author":"Abbot","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/0006-8993(80)91295-0","article-title":"The action of \u03b3-vinyl-GABA and \u03b3-acetylenic-GABA on the resting and stimulated release of GABA in vivo","volume":"191","author":"Bradford","year":"1980","journal-title":"Brain Res."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"7404","DOI":"10.1021\/jm0608715","article-title":"Fluorinated conformationally restricted \u03b3-aminobutyric acid aminotransferase inhibitors","volume":"49","author":"Lu","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"10848","DOI":"10.1002\/chem.201701443","article-title":"The Synthesis and Evaluation of Fluoro-, Trifluoromethyl-, and Iodomuscimols as GABA Agonists","volume":"23","author":"Cordes","year":"2017","journal-title":"Chemistry"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1021\/acschemneuro.8b00038","article-title":"Synthesis and Evaluation of a New (18)F-Labeled Radiotracer for Studying the GABA(B) Receptor in the Mouse Brain","volume":"9","author":"Naik","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1212\/WNL.0000000000205180","article-title":"VIGAB-STAT\u2014A Phase IIa Feasibility Trial of Irreversible GABA-transaminase Inhibition as Adjunct Treatment of Status Epilepticus After Cardiac Arrest (P4-2.003)","volume":"102","author":"Ahmad","year":"2024","journal-title":"Neurology"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jchromb.2016.11.016","article-title":"Determination of enantiomeric vigabatrin by derivatization with diacetyl-L-tartaric anhydride followed by ultra-high performance liquid chromatography-quadrupole-time-of-flight mass spectrometry","volume":"1040","author":"Zhao","year":"2017","journal-title":"J. Chromatogr. B"},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"L\u00f6scher, W. (2019). The epileptic gerbil. Neuronal networks and actions of antiepileptic drugs. Drugs for the Control of Epilepsy, CRC Press.","DOI":"10.1201\/9780429262623-13"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.drudis.2010.06.014","article-title":"Insights into the novel three \u2018D\u2019s of epilepsy treatment: Drugs, delivery systems and devices","volume":"15","author":"Pathan","year":"2010","journal-title":"Drug Discov. Today"},{"key":"ref_211","doi-asserted-by":"crossref","unstructured":"Mehdi, S. (2013). Covalent Enzyme Inhibition in Drug Discovery and Development. Enz. Technol., 81\u2013129.","DOI":"10.1002\/9781118739907.ch3"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3891\/acta.chem.scand.36b-0669","article-title":"Syntheses of Some Cyclic Amino Acids Structurally Related to the GABA Analogue Homo-beta-Proline","volume":"36","author":"Labouta","year":"1982","journal-title":"Acta Chem. Scand."},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Yasir, M., Park, J., Lee, Y., Han, E.-T., Park, W.S., Han, J.-H., Kwon, Y.-S., Lee, H.-J., and Chun, W. (2023). Discovery of GABA Aminotransferase Inhibitors via Molecular Docking, Molecular Dynamic Simulation, and Biological Evaluation. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242316990"},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"Yasir, M., Park, J., Han, E.-T., Park, W.S., Han, J.-H., Kwon, Y.-S., Lee, H.-J., and Chun, W. (2023). Computational exploration of the effects of mutations on GABA aminotransferase in GABA aminotransferase deficiency. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310933"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1177\/09727531231185991","article-title":"Recent progress in the development of new antiepileptic drugs with novel targets","volume":"30","author":"Belete","year":"2023","journal-title":"Ann. Neurosci."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"742","DOI":"10.3390\/futurepharmacol3040046","article-title":"Carrier-Mediated Delivery of Low-Molecular-Weight N-Containing Drugs across the Blood\u2013Brain Barrier or the Blood\u2013Retinal Barrier Using the Proton-Coupled Organic Cation Antiporter","volume":"3","author":"Tashima","year":"2023","journal-title":"Future Pharmacol."},{"key":"ref_217","unstructured":"Gentile, D. (2025, December 04). A Computational Approach for the Molecular Recognition of Novel Ophthalmic Prodrugs and Molecular Modelling of Sigma Receptor Ligands in Ocular Diseases. Available online: https:\/\/tesidottorato.depositolegale.it\/handle\/20.500.14242\/73926."},{"key":"ref_218","doi-asserted-by":"crossref","unstructured":"Yasir, M., Park, J., Choe, J., Han, J.-H., Han, E.-T., Park, W.S., and Chun, W. (2025). Structure-Guided Identification of JAK2 Inhibitors: From Similarity to Stability and Specificity. Future Pharmacol., 5.","DOI":"10.3390\/futurepharmacol5040066"},{"key":"ref_219","doi-asserted-by":"crossref","unstructured":"Yasir, M., Park, J., Han, E.-T., Han, J.-H., Park, W.S., Choe, J., and Chun, W. (2025). Integration of Deep Learning with Molecular Docking and Molecular Dynamics Simulation for Novel TNF-\u03b1-Converting Enzyme Inhibitors. Future Pharmacol., 5.","DOI":"10.3390\/futurepharmacol5040055"},{"key":"ref_220","doi-asserted-by":"crossref","unstructured":"Yasir, M., Park, J., Han, E.-T., Han, J.-H., Park, W.S., Choe, J., and Chun, W. (2025). Investigating Natural Product Inhibitors of IKK\u03b1: Insights from Integrative In Silico and Experimental Validation. Molecules, 30.","DOI":"10.3390\/molecules30092025"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12936-025-05259-z","article-title":"Structural comparison of human and Plasmodium proteasome \u03b25 subunits: Informing selective inhibitor design for anti-malaria agents","volume":"24","author":"Yasir","year":"2025","journal-title":"Malar. J."},{"key":"ref_222","doi-asserted-by":"crossref","unstructured":"Yasir, M., Park, J., Han, E.-T., Han, J.-H., Park, W.S., Hassan, M., Kloczkowski, A., and Chun, W. (2024). Discovery of novel TACE inhibitors using graph convolutional network, molecular docking, molecular dynamics simulation, and Biological evaluation. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0315245"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"38820","DOI":"10.1021\/acsomega.4c04886","article-title":"Identification of Potential Tryptase Inhibitors from FDA-Approved Drugs Using Machine Learning, Molecular Docking, and Experimental Validation","volume":"9","author":"Yasir","year":"2024","journal-title":"ACS Omega"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"20338","DOI":"10.1021\/acsomega.4c00820","article-title":"Discovery of novel aldose reductase inhibitors via the integration of ligand-based and structure-based virtual screening with experimental validation","volume":"9","author":"Yasir","year":"2024","journal-title":"ACS Omega"},{"key":"ref_225","doi-asserted-by":"crossref","unstructured":"Yasir, M., Park, J., Han, E.-T., Han, J.-H., Park, W.S., and Chun, W. (2024). Identification of malaria-selective proteasome \u03b25 inhibitors through pharmacophore modeling, molecular docking, and molecular dynamics simulation. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252211881"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s00894-020-04495-1","article-title":"In silico screening of GABA aminotransferase inhibitors from the constituents of Valeriana officinalis by molecular docking and molecular dynamics simulation study","volume":"26","author":"Park","year":"2020","journal-title":"J. Mol. Model."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"101835","DOI":"10.1016\/j.jsps.2023.101835","article-title":"Integrated virtual screening, molecular modeling and machine learning approaches revealed potential natural inhibitors for epilepsy","volume":"31","author":"Alshehri","year":"2023","journal-title":"Saudi Pharm. J."},{"key":"ref_228","doi-asserted-by":"crossref","unstructured":"Sinha, S., Dubey, M., Misal, S., Alavala, R.R., and CS, R. (2025). Computational Analyses of the Mechanism of Action of Antiepileptic Agents. Applications of Computational Tools in Drug Design and Development, Springer.","DOI":"10.1007\/978-981-96-4154-3_24"},{"key":"ref_229","doi-asserted-by":"crossref","unstructured":"Yasir, M., Park, J., Han, E.-T., Park, W.S., Han, J.-H., Choe, J., Hassan, M., Kloczkowski, A., and Chun, W. (2025). Computational Analysis of GAT1 Mutations: Functional Consequences from Molecular Dynamics and Binding Free Energy Calculations. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262311339"},{"key":"ref_230","doi-asserted-by":"crossref","unstructured":"Chan, B.W., Lynch, N.B., Tran, W., Joyce, J.M., Savage, G.P., Meutermans, W., Montgomery, A.P., and Kassiou, M. (2024). Fragment-based drug discovery for disorders of the central nervous system: Designing better drugs piece by piece. Front. Chem., 12.","DOI":"10.3389\/fchem.2024.1379518"},{"key":"ref_231","doi-asserted-by":"crossref","unstructured":"Wasko, M.J., Pellegrene, K.A., Madura, J.D., and Surratt, C.K. (2015). A role for fragment-based drug design in developing novel lead compounds for central nervous system targets. Front. Neurol., 6.","DOI":"10.3389\/fneur.2015.00197"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"2503646","DOI":"10.1002\/adma.202503646","article-title":"Application of Novel Drug-Delivery Strategies in Neurological Disorders","volume":"37","author":"Li","year":"2025","journal-title":"Adv. Mater."},{"key":"ref_233","doi-asserted-by":"crossref","unstructured":"Gernert, M., and Feja, M. (2020). Bypassing the blood\u2013brain barrier: Direct intracranial drug delivery in epilepsies. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12121134"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/157015907780866938","article-title":"Cell and gene therapies for refractory epilepsy","volume":"5","author":"Boison","year":"2007","journal-title":"Curr. Neuropharmacol."},{"key":"ref_235","unstructured":"Police, A. (2020). Approaches to Alleviate the Vigabatrin Induced Retinal Toxicity. [Ph.D. Thesis, The University of Mississippi]."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-0404.2012.01684.x","article-title":"Vigabatrin-associated retinal damage\u2013potential biochemical mechanisms","volume":"126","author":"Heim","year":"2012","journal-title":"Acta Neurol. Scand."},{"key":"ref_237","doi-asserted-by":"crossref","unstructured":"L\u00f6scher, W. (2021). Single-target versus multi-target drugs versus combinations of drugs with multiple targets: Preclinical and clinical evidence for the treatment or prevention of epilepsy. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.730257"},{"key":"ref_238","doi-asserted-by":"crossref","unstructured":"Zhu, X.-H., Lee, B.-Y., Tuite, P., Coles, L., Sathe, A.G., Chen, C., Cloyd, J., Low, W.C., Steer, C.J., and Chen, W. (2021). Quantitative assessment of occipital metabolic and energetic changes in Parkinson\u2019s patients, using in Vivo 31P MRS-based metabolic imaging at 7T. Metabolites, 11.","DOI":"10.3390\/metabo11030145"},{"key":"ref_239","doi-asserted-by":"crossref","unstructured":"Auriat, A.M., Neva, J.L., Peters, S., Ferris, J.K., and Boyd, L.A. (2015). A review of transcranial magnetic stimulation and multimodal neuroimaging to characterize post-stroke neuroplasticity. Front. Neurol., 6.","DOI":"10.3389\/fneur.2015.00226"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jcpp.12435","article-title":"Research review: Use of EEG biomarkers in child psychiatry research\u2013current state and future directions","volume":"57","author":"Loo","year":"2016","journal-title":"J. Child Psychol. Psychiatry"},{"key":"ref_241","doi-asserted-by":"crossref","unstructured":"Ewen, J.B., Sweeney, J.A., and Potter, W.Z. (2019). Conceptual, regulatory and strategic imperatives in the early days of EEG-based biomarker validation for neurodevelopmental disabilities. Front. Integr. Neurosci., 13.","DOI":"10.3389\/fnint.2019.00045"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/14737175.2023.2216385","article-title":"Efficacy and safety of vigabatrin in patients with tuberous sclerosis complex and infantile epileptic spasm syndrome: A systematic review","volume":"23","author":"Prezioso","year":"2023","journal-title":"Expert Rev. Neurother."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2018.09.016","article-title":"High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex","volume":"148","author":"Hussain","year":"2018","journal-title":"Epilepsy Res."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.pediatrneurol.2015.04.012","article-title":"Vigabatrin as first-line treatment for infantile spasms not related to tuberous sclerosis complex","volume":"53","author":"Jones","year":"2015","journal-title":"Pediatr. Neurol."},{"key":"ref_245","doi-asserted-by":"crossref","unstructured":"Li, X., and Slesinger, P.A. (2021). GABAB receptors and drug addiction: Psychostimulants and other drugs of abuse. Behavioral Neurobiology of GABAB Receptor Function, Springer.","DOI":"10.1007\/7854_2020_187"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1001\/jamapsychiatry.2013.872","article-title":"A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence","volume":"70","author":"Somoza","year":"2013","journal-title":"JAMA Psychiatry"}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/12\/1032\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T09:18:39Z","timestamp":1765444719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/12\/1032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":246,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["cimb47121032"],"URL":"https:\/\/doi.org\/10.3390\/cimb47121032","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]}}}